Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 4-Week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-Daily in Subjects With COPD.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Darotropium bromide (Primary) ; Vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GSK
- 25 Mar 2009 Actual patient number (61) added as reported by ClinicalTrials.gov.
- 25 Mar 2009 Actual patient number (61) added as reported by ClinicalTrials.gov.
- 25 Mar 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.